Viatris develops and sells generic and off-patent branded pharmaceutical products across a broad global portfolio, formed through the merger of Mylan and Pfizer's Upjohn division, which held many of Pfizer's older, off-patent branded drugs. Its business combines traditional generic drugs, which compete primarily on price once patent protection on branded originals expires, with older branded products that still carry some brand recognition despite facing generic competition themselves. Viatris sells across a large number of countries, giving it geographic diversification beyond any single national market or regulatory regime, though this global generic drug business tends to carry lower margins than research-driven branded pharmaceutical companies. The company's revenue and profitability depend on managing a large portfolio of mature products facing ongoing pricing pressure, along with its ability to bring new generic and complex generic products to market as other companies' patents expire.